Merck & Company (MRK): $55.98 million was the positive money flow into the stock on Monday and the up/down ratio of ticks was also in favor of the bulls at 2.09. The value of trades done on upticks was $107.39 million, whereas, trades done on downticks were valued at $51.41 million. Money flows are calculated as the dollar value of composite uptick trades minus the dollar value of downtick trades. large traders, also sometimes called as the smart money, block traded $56.23 million worth stocks on upticks, which is a bullish indication. The money flow in block trades was $56.23 million. Merck & Company (MRK) fell $0.03 traded at $63.32, a change of -0.05% over the previous day. The stock is -0.85% for the week.
Shares of Merck & Co., Inc. rose by 0.73% in the last five trading days and 6.19% for the last 4 weeks. Merck & Co., Inc. is up 16.81% in the last 3-month period. Year-to-Date the stock performance stands at 21.91%.
Merck & Company (NYSE:MRK): The stock opened at $63.35 on Monday but the bulls could not build on the opening and the stock topped out at $63.75 for the day. The stock traded down to $63.21 during the day, due to lack of any buying support eventually closed down at $63.32 with a loss of -0.05% for the day. The stock had closed at $63.35 on the previous day. The total traded volume was 6,650,069 shares.
In a related news, The officer (EVP & Chief Info Officer), of Merck & Co., Inc., Golestani Clark had unloaded 3,000 shares at $63.03 per share in a transaction on August 10, 2016. The total value of transaction was $189,090. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing.
Merck & Co., Inc. is a global health care company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. The Companys Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. The Animal Health segment discovers, develops, manufactures and markets animal health products, including vaccines. The Companys animal health products are sold to veterinarians, distributors and animal producers.